Clinical Trial Update: Healthy-donor Microbiome MTP-101-C in Steroid Relapse/Refractory Immune-related Cutaneous Adverse Events (irCAEs) and Immune-mediated Colitis (IMC) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating healthy-donor microbiome MTP-101-C for steroid-relapse/refractory immune-related adverse events and immune-mediated colitis; currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune-mediated Colitis
• Immune-related Dermatitis

Drugs mentioned

• MTP-101-C

Snippet

Sponsor: Diwakar Davar | Conditions: Immune-mediated Colitis (IMC), Immune-related Dermatitis | Phase 2 | Status: RECRUITING